– Email Summary: Vaccines: The Week in Review is available as a weekly email summary: please send your request to email@example.com.
– pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_30 March 2013_PDF
– Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
– Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria selected Nafsiah Mboi of Indonesia to be its next Board Chair and Mireille Guigaz of France as its next Board Vice-Chair. Both will begin a two-year term starting in late June, 2013. Dr Nafsiah Mboi is the Minister of Health for the Republic of Indonesia. She has more than 40 years of experience in national and global public health, including a full career as a civil servant in the Ministry of Health. Madame Guigaz most recently served as France’s Ambassador for the fight against HIV/AIDS and communicable diseases, representing France on the Board of the Global Fund, a position she also held in the early days of the Global Fund. She has served on the Board’s Strategy, Investment and Impact Committee and its Audit and Ethics Committee, as well as on the Boards of UNITAID and Roll Back Malaria. Dr Nafsiah and Mme Guigaz will serve in a personal capacity. In their new roles, they will represent the interests of the entire Global Fund, instead of representing their home country. Dr Nafsiah and Mme Guigaz were selected by unanimous electronic vote by the Board on 18 March 2013.
GAVI said it received an additional €1 million commitment from the “la Caixa” Foundation, marking the 5th anniversary of the formal partnership between GAVI and “la Caixa.” The commitment brings the total amount donated by the Spanish bank, its employees and business partners to more than € 17 million (about US$ 22 million), “helping immunise more than 2.1 million children”
– See more at: http://www.gavialliance.org/library/news/press-releases/2013/gavi-partner–la-caixa–foundation-heightens-commitment-to-children-s-vaccination/#sthash.8mWig3mC.dpuf
IFFIm: New Vaccine Bonds for Japanese Investors – 28 March 2013
The International Finance Facility for Immunisation (IFFIm), GAVI Alliance, World Bank and Daiwa Securities Group jointly announced the first issuance and sale of “vaccine bonds” for 2013 targeted for Japanese investors.
GlaxoSmithKline (GSK) and The Texas A&M University System announced that the U.S. Department of Health and Human Services (DHHS) approved the establishment of a US$91 million influenza vaccine manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, Texas. The TAMUS influenza vaccines manufacturing center “will afford GSK the capabilities to eventually manufacture influenza vaccine based on a proprietary cell-culture line, EB66…The cell-culture process will supplement the vaccine supply from eggs, and facilitate a rapid national vaccine response in the event of a pandemic.”
The Weekly Epidemiological Record (WER) for 29 March 2013, vol. 88, 13 (pp. 137–144) includes:
– Update on human cases of influenza at the human–animal interface, 2012